Re: 再论 mRNA 新冠病毒疫苗的有效性
发表于 ： 11 2月 2026, 21:19
疫苗产生的蛋白质，和得新冠产生的蛋白质是一样的，要不溶解都不溶解，你躲不掉的
疫苗产生的蛋白质，和得新冠产生的蛋白质是一样的，要不溶解都不溶解，你躲不掉的
如果mrna疫苗和灭活疫苗没啥本质区别，为啥会得到炸弹奖？
你可以不断绕圈子，我也没空浪费时间，你们喜欢mrna疫苗就多打点，但是不要强迫我们不想打的人打，就这么简单。
阿毛啊，吃到肚子里的蛋白质，大多数都被消化降解了。但所谓的 "mRNA 疫苗" 却不同。"mRNA 疫苗" 通过脂质体把 mRNA 转送进人细胞内，然后在细胞内以 mRNA 为模板翻译合成病毒的蛋白质。研究发现，脂质体包裹的 mRNA 甚至能跑到大脑中，这后果就比较严重了:
https://www.sciencedirect.com/science/a ... 682500195X
更可怕的是，在打过疫苗之后，过了17个月，仍然能在脑动脉中检测到病毒刺突蛋白。
Highlights
另外，并不是所有吃到肚子里的蛋白质都能降解，比如“疯牛病”是通过朊蛋白感染的。朊蛋白极难被常规消化酶分解、胃酸破坏或高温烹煮灭活。所以，虽然疯牛病病原其本质是蛋白质，但其抗降解特性使它们能穿过肠道屏障进入血液和神经系统致病。
https://zh.wikipedia.org/zh-cn/%E7%89%9 ... 5%E8%AE%8A
shepherd17 写了： ↑昨天, 21:28阿毛啊，吃到肚子里的蛋白质，大多数都被消化降解了。但所谓的 "mRNA 疫苗" 却不同。"mRNA 疫苗" 通过脂质体把 mRNA 转送进人细胞内，然后在细胞内以 mRNA 为模板翻译合成病毒的蛋白质。研究发现，脂质体包裹的 mRNA 甚至能跑到大脑中，这后果就比较严重了:
SARS‑CoV‑2 刺突蛋白在脑动脉中的表达：mRNA 疫苗接种后出血性中风的潜在影响
Expression of SARS-CoV-2 spike protein in cerebral Arteries: Implications for hemorrhagic stroke Post-mRNA vaccination
https://www.sciencedirect.com/science/a ... 682500195X
更可怕的是，在打过疫苗之后，过了17个月，仍然能在脑动脉中检测到病毒刺突蛋白。
Highlights
- Spike protein expression was detected in 43.8% of vaccinated patients.
- SARS-CoV-2 spike protein persists in cerebral arteries up to 17 months post-vaccination.
- Spike protein was expressed in the intima of the cerebral arteries.
- In situ hybridization confirmed vaccine- and virus-derived spike protein mRNA.
- Findings highlight concerns about mRNA vaccine biodistribution and long-term safety.
另外，并不是所有吃到肚子里的蛋白质都能降解，比如“疯牛病”是通过朊蛋白感染的。朊蛋白极难被常规消化酶分解、胃酸破坏或高温烹煮灭活。所以，虽然疯牛病病原其本质是蛋白质，但其抗降解特性使它们能穿过肠道屏障进入血液和神经系统致病。
https://zh.wikipedia.org/zh-cn/%E7%89%9 ... 5%E8%AE%8A
得了新冠，这些mrna（本来就是病毒的），是不是也一样入脑呢
这个光看你说的几句，逻辑上不通：
“mRNA 疫苗所产生的蛋白是无法吸收溶解的”, 那这个意思是说产生的抗体(一种蛋白)是hydrophobic. 抗体是产生在肌肉等组织内，既然不溶于水，那就不会进血液。
那下一句“慢慢会堆积在血管细微处”根本不会发生。
至于特定Cohort 的副作用研究，例如你说的心脏病人群，其实设计个双盲试验不难。
resso 写了： ↑昨天, 21:30shepherd17 写了： ↑昨天, 21:28阿毛啊，吃到肚子里的蛋白质，大多数都被消化降解了。但所谓的 "mRNA 疫苗" 却不同。"mRNA 疫苗" 通过脂质体把 mRNA 转送进人细胞内，然后在细胞内以 mRNA 为模板翻译合成病毒的蛋白质。研究发现，脂质体包裹的 mRNA 甚至能跑到大脑中，这后果就比较严重了:
SARS‑CoV‑2 刺突蛋白在脑动脉中的表达：mRNA 疫苗接种后出血性中风的潜在影响
Expression of SARS-CoV-2 spike protein in cerebral Arteries: Implications for hemorrhagic stroke Post-mRNA vaccination
https://www.sciencedirect.com/science/a ... 682500195X
更可怕的是，在打过疫苗之后，过了17个月，仍然能在脑动脉中检测到病毒刺突蛋白。
Highlights
- Spike protein expression was detected in 43.8% of vaccinated patients.
- SARS-CoV-2 spike protein persists in cerebral arteries up to 17 months post-vaccination.
- Spike protein was expressed in the intima of the cerebral arteries.
- In situ hybridization confirmed vaccine- and virus-derived spike protein mRNA.
- Findings highlight concerns about mRNA vaccine biodistribution and long-term safety.
另外，并不是所有吃到肚子里的蛋白质都能降解，比如“疯牛病”是通过朊蛋白感染的。朊蛋白极难被常规消化酶分解、胃酸破坏或高温烹煮灭活。所以，虽然疯牛病病原其本质是蛋白质，但其抗降解特性使它们能穿过肠道屏障进入血液和神经系统致病。
https://zh.wikipedia.org/zh-cn/%E7%89%9 ... 5%E8%AE%8A得了新冠，这些mrna（本来就是病毒的），是不是也一样入脑呢
数量上的区别呢？尤其刚打过mRNA疫苗？
刚去Pfizer官网去查caution, 他们有详细列出：
COMIRNATY® (COVID-19 Vaccine, mRNA) Official HCP Website | Safety Info
https://comirnatyhcp.pfizerpro.com/?cmp ... GtEALw_wcB
Important Safety Information
Do not administer COMIRNATY® (COVID-19 Vaccine, mRNA) to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of COMIRNATY or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of a Pfizer-BioNTech COVID-19 vaccine.
Management of Acute Allergic Reactions
Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of COMIRNATY.
Myocarditis and Pericarditis
Postmarketing data from use of authorized or approved mRNA COVID-19 vaccines, including COMIRNATY, have demonstrated increased risks of myocarditis and pericarditis, with onset of symptoms typically in the first week following vaccination. The observed risk has been highest in males 12 years through 24 years of age.
Syncope
Syncope (fainting) may occur in association with administration of injectable vaccines, including COMIRNATY. Procedures should be in place to avoid injury from fainting.
Altered Immunocompetence
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to COMIRNATY.
Limitation of Vaccine Effectiveness
COMIRNATY may not protect all vaccine recipients.
Adverse Reactions
Most commonly reported adverse reactions after a dose:
12 years of age and older (≥10%) were pain at the injection site (up to 90.5%), fatigue (up to 77.5%), headache (up to 75.5%), chills (up to 49.2%), muscle pain (up to 45.5%), joint pain (up to 27.5%), fever (up to 24.3%), injection site swelling (up to 11.8%), and injection site redness (up to 10.4%).
5 years through 11 years of age (≥5%) were pain at the injection site (up to 83.8%), fatigue (up to 51.9%), headache (up to 38.4%), injection site redness (up to 25.9%), injection site swelling (up to 20%), muscle pain (up to 18.1%), chills (up to 13.3%), fever (up to 7.8%), and joint pain (up to 7.6%).